A Phase 1/2 Study of SC-43 in Combination With Cisplatin
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
SC-43 is STAT3 inhibitor. Based on the phase I data of SC-43 monotherapy, this is a Phase
1/2, Open-label, Study to Investigate the Safety, Tolerability, and Efficacy of SC-43
Administered in Combination with Cisplatin in Subjects with Advanced or Refractory Non-small
Cell Lung Cancer or Biliary Tract Carcinoma